CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The CCTG Pharmacy Network is actively seeking pharmacy representation for the following:
The Steering Group is responsible for providing leadership for the Pharmacy Network. Please review the terms of reference at: Steering group terms of reference.
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Gastrointestinal Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gastrointestinal Disease Site Committee, the Gastrointestinal Disease Site Executive Committee, and the CCTG Patient Representative Committee.
The American Society for Radiation Oncology (ASTRO) annual general meeting was held from September 27 ‒ October 1, 2025. Below are some of the research presentations that CCTG played a role in.
CRC6 (CALGB C80702): A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer trial has permanently closed.
IND.238 sub-study A is a phase II study of Durvalumab in patients who discontinued prior checkpoint therapy due to immune related toxicity has closed to accrual. Treatment and follow up for sub-study A patients will continue as per protocol.
MAC25 (NRG-BR004): A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer trial has closed.
